Proceedings of the First International Conference on Health, Social Sciences and Technology (ICoHSST 2020)

Cost-Effectiveness Analysis of Antihypertensive Drug Use in Hypertension-Diabetes Mellitus and Hypertension-Heart Failure Inpatients at a Government Hospital in Yogyakarta, Indonesia

Authors
Faridah Baroroh, Andriana Sari, Khansa Zakiyatul Laili, Dina Putri Permatasari
Corresponding Author
Faridah Baroroh
Available Online 19 April 2021.
DOI
10.2991/assehr.k.210415.010How to use a DOI?
Keywords
Cost-effectiveness analysis, antihypertensive, inpatient, hypertension-diabetes mellitus, hypertension-heart failure
Abstract

Hypertension and diabetes mellitus are the leading risk factors for cardiovascular diseases, which are increasing rapidly throughout the world. Hypertension is a non-communicable disease that remains a health problem in Indonesia, with a prevalence of up to 34.11% in 2018. This research was intended to identify cost- effective antihypertensive medication for inpatients with hypertension-diabetes mellitus and hypertension-heart failure. The research method used a retrospective cohort design and measured blood pressure (BP) 72 hours after treatment as the outcome of the observation. Based on a payer perspective, the medical expense was calculated from direct medical costs written in billing invoices. The research subjects were inpatients with hypertension-diabetes mellitus and hypertension-heart failure at a government hospital in Yogyakarta, Indonesia. In the cost- effectiveness analysis, Incremental Cost-Effectiveness Ratio (ICER) was calculated by dividing the difference in cost by the difference in the outcome of hypertension treatment.In the antihypertensive medication of hypertension-diabetes mellitus inpatients, angiotensin-receptor blockers/ calciumchannel blockers (ACB-CCB) were found to be more cost-effective than CCB with incremental costs of IDR 191,405/488,864 for every mmHg decrease of systolic/diastolic BP. Meanwhile, in the antihypertensive treatment of hypertension-heart failure inpatients, the combination of angiotensin-converting- enzyme inhibitors (ACEI) and diuretics was more cost-effective than ACEI-CCB (ICERs= IDR 8,303,483/-39,856,718 per mmHg) and ARB (ICERs= IDR 3,627,694/-2,380,075 per mmHg).In conclusion, ARB-CCB is a cost-effective medication for hypertension-diabetes mellitus inpatients, while ACEI-Diuretics offers a cost-effective hypertensive treatment for hypertension-heart failure inpatients.

Copyright
© 2021, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

Volume Title
Proceedings of the First International Conference on Health, Social Sciences and Technology (ICoHSST 2020)
Series
Advances in Social Science, Education and Humanities Research
Publication Date
19 April 2021
ISBN
978-94-6239-365-3
ISSN
2352-5398
DOI
10.2991/assehr.k.210415.010How to use a DOI?
Copyright
© 2021, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - CONF
AU  - Faridah Baroroh
AU  - Andriana Sari
AU  - Khansa Zakiyatul Laili
AU  - Dina Putri Permatasari
PY  - 2021
DA  - 2021/04/19
TI  - Cost-Effectiveness Analysis of Antihypertensive Drug Use in Hypertension-Diabetes Mellitus and Hypertension-Heart Failure Inpatients at a Government Hospital in Yogyakarta, Indonesia
BT  - Proceedings of the First International Conference on Health, Social Sciences and Technology (ICoHSST 2020)
PB  - Atlantis Press
SP  - 41
EP  - 45
SN  - 2352-5398
UR  - https://doi.org/10.2991/assehr.k.210415.010
DO  - 10.2991/assehr.k.210415.010
ID  - Baroroh2021
ER  -